Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Wells Fargo Remains a Buy on Iovance Biotherapeutics (IOVA)
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report) yesterday. The company’s shares ...
STAT18h
On JPM Day 3, one topic was on everyone’s mind
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
STAT21h
Editas, after slow start, outlines plan to catch other CRISPR companies
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
Polar vortex to plunge US into freezing temperatures
A polar vortex is expected to cause temperatures to fall below freezing across most of the United States starting this weekend. According to the National Weather Service, bitter cold will spread ...